CNS PharmaceuticalsCNSP
About: CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
Employees: 3
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
8,100% more capital invested
Capital invested by funds: $75.3K [Q3] → $6.17M (+$6.1M) [Q4]
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
62% more funds holding
Funds holding: 13 [Q3] → 21 (+8) [Q4]
2.88% more ownership
Funds ownership: 1.79% [Q3] → 4.68% (+2.88%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CNSP.
Financial journalist opinion
Based on 3 articles about CNSP published over the past 30 days









